Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Ordina per
Keyphrases
Budget Impact Analysis
100%
Ischemic Stroke
100%
Euro
100%
Atrial Fibrillation
100%
Medical Devices
100%
Cumulative Costs
66%
Warfarin
50%
Break-even Point
50%
Antiplatelet Drugs
33%
Anticoagulants
33%
Left Atrial Appendage
33%
Budget Impact
33%
Clinical Trials
16%
Italian National Health Service
16%
Pharmacological Therapy
16%
Italian Guidelines
16%
European Guidelines
16%
Independent Risk Factors
16%
Stroke Risk
16%
Risk-benefit
16%
Cost-effectiveness
16%
Arrhythmia
16%
Italian Hospital
16%
Overall Mortality
16%
Making Decisions
16%
Drug Class
16%
Non-valvular Atrial Fibrillation
16%
Thromboembolic Risk
16%
Intolerant
16%
Delivery System
16%
Long-term Sustainability
16%
Direct Thrombin Inhibitors
16%
Anticoagulant Drugs
16%
Stroke Prophylaxis
16%
Follow-up Costs
16%
Model Scenarios
16%
Net Impacts
16%
Cost-effectiveness Analysis
16%
Atrial Fibrillation Treatment
16%
85-year-old
16%
Budget Impact Model
16%
Healthcare Expenditure
16%
Factor Xa Inhibitors
16%
CHADS2 Score
16%
Catheter-related
16%
Ictus
16%
Chronic Anticoagulant Therapy
16%
Dabigatran
16%
Risk Factors for Stroke
16%
Cohort Approach
16%
Oral Drugs
16%
Thromboembolism
16%
Decision Basis
16%
Postmarketing
16%
Left Atrial Occlusion
16%
Marketing Risk
16%
Oral Anticoagulant Therapy
16%
Cost per QALY
16%
Nursing and Health Professions
Atrial Fibrillation
100%
Brain Ischemia
100%
Medical Device
100%
Anticoagulant Agent
66%
Cerebrovascular Accident
66%
Warfarin
50%
Cost Effectiveness Analysis
33%
Base
33%
Thromboembolism
33%
Antithrombocytic Agent
33%
Anticoagulant Therapy
33%
Socialized Medicine
16%
Catheter
16%
Drug Therapy
16%
Practice Guideline
16%
Contraindication
16%
CHADS2 Score
16%
Health Care Cost
16%
Heart Arrhythmia
16%
Quality Adjusted Life Year
16%
Dabigatran
16%
Thrombin Inhibitor
16%
Medicine and Dentistry
Health Care Cost
100%
Brain Ischemia
100%
Atrial Fibrillation
100%
Medical Device
100%
Apoplexy
33%
Antithrombotic
25%
Warfarin
25%
Base
16%
Antiplatelet Drug
16%
Cost-Effectiveness Analysis
16%
Anticoagulant Therapy
16%
Thromboembolism
16%
National Health Service
8%
Clinical Trial
8%
Drug Therapy
8%
Health Care
8%
Contraindication
8%
Cardiac Dysrhythmia
8%
Dabigatran
8%
Direct Thrombin Inhibitor
8%
Anticoagulant
8%
Quality Adjusted Life Year
8%
CHADS2 Score
8%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Ischemia
100%
Atrial Fibrillation
100%
Anticoagulant Agent
83%
Cerebrovascular Accident
66%
Warfarin
50%
Base
33%
Antithrombocytic Agent
33%
Thromboembolism
33%
Clinical Trial
16%
Pharmacotherapy
16%
Heart Arrhythmia
16%
Dabigatran
16%
Thrombin Inhibitor
16%